Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma
Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P
International journal of cancer · 343 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2010-05-06 · Int J Cancer · vol. 128 · número 6 · págs. 1414–1424
- Editorial
- Wiley
- Citado
- 499 citas · más que el 100% de estudios similares · 26.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 72 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Nutritional Studies and Diet · Skin Protection and Aging
- Palabras clave
- 25-hydroxyvitamin D, vitamin D status, colorectal cancer, breast cancer, prostate cancer, colorectal adenoma, cancer risk, dose-response relationship, confounding factors
- MeSH
- humans, breast neoplasms, colorectal neoplasms, prostatic neoplasms, vitamin d, risk factors, case-control studies, prospective studies, aged, middle aged, female, male
8 autores
- Sara Gandini🇮🇹European Institute of Oncology
- Mathieu Boniol🇫🇷International Prevention Research Institute
- Jari K. Haukka🇫🇮University of Helsinki
- Graham B Byrnes🇫🇷Centre international de recherche sur le cancer
- Brian Cox🇳🇿University of Otago
- Mary Jane Sneyd🇳🇿University of Otago
- Patrick Mullie🇧🇪KU Leuven
- Philippe Autier🇫🇷 · autor de correspondenciaInternational Prevention Research Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Epidemiological studies have suggested a reduced risk of several cancers associated with high vitamin D status. We performed a systematic review with meta-analyses of observational studies of serum 25-hydroxyvitamin D level and colorectal, breast and prostate cancer and colonic adenoma. The literature of December 2009 was searched without language restriction. The meta-regression analysis was done to compute dose-response effects. Because in case-control studies, serum 25-hydroxyvitamin D level is measured after the diagnosis of cancer, separate analyses for case-control and prospective studies were done. We identified 35 independent studies. The seven studies on colorectal adenomas were heterogeneous in terms of endpoint and control for major confounding factors, and we did not perform a meta-analysis of these data. The summary relative risk (SRR) and (95% confidence interval) for a 10 ng/ml increase in serum 25-hydroxyvitamin D was 0.85 (0.79; 0.91) for colorectal cancer (2,630 cases in 9 studies); 0.89 (0.81;0.98) for breast cancer (6,175 cases in 10 studies); and 0.99 (0.95;1.03) for prostate cancer (3,956 cases in 11 studies). For breast cancer, case-control studies (3,030 cases) had major limitations and obtained SRR of 0.83 (0.79; 0.87) whereas SRR of prospective studies (3,145 cases) was 0.97 (0.92; 1.03). For colorectal and breast cancer, differences between cases and controls in the season of blood draw or in overweight/obesity or physical inactivity could not explain the results. In conclusion, a consistent inverse relationship between serum 25-hydroxyvitamin D levels and colorectal cancer was found. No association was found for breast and prostate cancer.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.